Reflexionen nach dem 36. „San Antonio Breast Cancer Symposium“ – Was gibt es Neues?

• Literatur

• 1 Badwe R, Parmar V, Hawaldar R et al. Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial. SABCS 2013: S2-02
• 2 Soran A, Ozmen V, Ozbas S et al. Early follow up of a randomized trial evaluating resection of the primary breast tumor in women presenting with de novo stage IV breast cancer; Turkish study (protocol MF07–01). SABCS 2013: S2-03
• 3 Kunkler IH, Williams LW, Jack W et al. The PRIME 2 trial: Wide local excision and adjuvant hormonal therapy ± postoperative whole breast irradiation in women ≥ 65 years with early breast cancer managed by breast conservation. SABCS 2013: S2-01
• 4 Houssami N, Macaskill P, Marinovich ML et al. The association of surgical margins and local recurrence in women with early-stage invasive breast cancer treated with breast-conserving therapy: a meta-analysis. Ann Surg Oncol 2014; 21: 717-730
• 5 Hurvitz S, Miller JM, Dichmann R et al. Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and / or lapatinib in patients with Her2+ breast cancer (trio-uS B07). SABCS 2013: S1-02
• 6 Sikov WM, Berry DA, Perou CM et al. Impact of the addition of carboplatin (Cb) and / or bevacizumab (B) to neoadjuvant weekly paclitaxel (P) followed by dose-dense AC on pathologic complete response (pCR) rates in triple-negative breast cancer (TNBC): CALGB 40 603 (Alliance). SABCS 2013: S5-01
• 7 Slamon DJ, Swain SM, Buyse M et al. Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. SABCS 2013: S1-03
• 8 Tolaney SM, Barry WT, Dang CT et al. A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC). SABCS 2013: S1-04
• 9 Cognetti F, Bruzzi P, De Placido S et al. Epirubicin and cyclophosphamide (EC) followed by paclitaxel (T) versus fluorouracil, epirubicin and cyclophosphamide (FEC) followed by T, all given every 3 weeks or 2 weeks, in node-positive early breast cancer (BC) patients (pts). Final results of the Gruppo Italiano Mammella (GIM)-2 randomized phase III study. SABCS 2013: S5-06
• 10 Coleman R, Gnant M, Paterson A et al. Effects of bisphosphonate treatment on recurrence and cause-specific mortality in women with early breast cancer: A meta-analysis of individual patient data from randomised trials. SABCS 2013: S4-07
• 11 Mackey JR, Ramos-Vazquez M, Lipatov O et al. Primary results of ROSE / TRIO-12, a randomized placebo controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer. SABCS 2013: S5-04
• 12 Smerage JB, Barlow WE, Hayes DF et al. SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment. SABCS 2013: S5-07
• 13 Cuzick J, Sestak I, Forbes JF et al. First results of the International breast cancer intervention study II (IBIS-II): A multicentre prevention trial of anastrozole versus placebo in postmenopausal women at increased risk of developing breast cancer. SABCS 2013: S3-01
• 14 Henry NL, Kidwell K, Hayes DF et al. Associations between baseline patient-reported symptoms and discontinuation of adjuvant aromatase inhibitor (AI) therapy. SABCS 2013: S3-02
• 15 Irwin ML, Cartmel B, Gross C et al. Randomized trial of exercise vs. usual care on aromatase inhibitor-associated arthralgias in women with breast cancer: The hormones and physical exercise (HOPE) study. SABCS 2013: S3-03